Other than of course raising funds, what's your next operational steps - (a) what are you working on that doesn't require you to raise beyond $1M and (b) what's key item you'll work on upon raising $1M?

James, thank you for asking. I want to make sure I answer this with precision because milestone-based thinking is exactly how we run this company.Our current Wefunder raise targets $300K, serving as a bridge to a $ 5M-priced seed round we are actively building toward. So let me answer in those terms, because that is the honest picture:We are in the final stages of analytical validation for our Strep A assay, while advancing our manufacturing partnership and building our FDA pre-submission. Th...

Hello, I have some questions. I apologize if these were already answered in the pitch. What specific FDA pathway do you expect for the at-home Strep A test, and what milestones remain before submission and clearance? The pitch deck says q2 2026 for this “de novo vs 510k” How m...

Thank you, Ali, for these questions. This is exactly the kind of diligence we welcome, and I will answer each one directly.On the FDA pathway, we are targeting 510(k) clearance for our at-home Strep A test. The Q2 2026 date in the deck has been updated, and our current near-term milestone is a Q-sub meeting with the FDA, which is the formal pre-submission step that aligns us with the agency on our pathway and data requirements before we proceed to submission.For clinical samples, we are progr...

Invest in Anywhere Dx

At-home diagnostics for time-sensitive infections: starting with strep

FIRST GOAL HIT (You can still invest)

$243,537

raised from 64 investors

INVEST

min $100

INVESTMENT TERMS

Future Equity

$5M valuation cap 20% discount

$250, $1K, $10K, $100K, $250K

anywhere.health

Boston, MA

What Investors Say

LEAD INVESTOR

Invested $20,000 this round

With a career in finance and experience as an angel investor, I've evaluated many opportunities and AnywhereDX stands out. As a mother myself, I know the uncertainty of watching your child struggle through a sore throat at 2am, not knowing if it's strep and wondering whether to wait it out or make a trip to urgent care. Co-founder Nathalya felt exactly that. A mother of four who lived this problem firsthand and decided to build the solution. With 20+ years scaling businesses, she has the conviction and the experience to make it real. Alongside her is co-founder Dr. Michael Mina, former Harvard professor and the leading global voice on rapid diagnostics, who advised the White House and Congress during COVID-19. What they've built is remarkable: a lab-grade strep test you can take at home. No swab, no scanner, no lab. A soft pad in the cheek, a result in 25 minutes, read like a pregnancy test. They have expertise and genuine human purpose. I personally invested because I believe in this team and this mission.

What People Say

Anywhere Dx

Quick facts

Team profiles

Featured investor profiles

$243,537

What Investors Say